Glaucoma Drug Reduces IOP Spike After Anti-VEGF Injections
Prophylaxis with brimonidine prevents sharp increases in IOP in patients who undergo intravitreal injections with anti-vascular endothelial growth factor (anti-VEGF), according to a new study, as reported by Reuters.
“Most importantly, our findings demonstrate that brimonidine also plays a protective role by significantly reducing the risk of eyes reaching very elevated IOPs in the range of 70-80 mmHg, and thus reduces the need for post-injection anterior chamber (AC) paracentesis,” said Dr. Efrem Mandelcorn of the University of Toronto.
“Given that administration of topical prophylaxis only 20 minutes prior to injection was shown to have hypotensive efficacy, it can be easily incorporated into current routine of ophthalmologists in a busy practice,” he told Reuters Health by email.